An Investigation of Strategies to Understand and Optimize the Antidepressant Effects of Psilocybin (The OPTIMIZE Study)

Phase: PHASE2 | Sponsor: Charles Raison | Compound: Psilocybin

Status

recruiting

Institution

Charles Raison

Start date

2025-05-13

End date

2029-05-01

Registry ID

NCT06512194

View trial record

Tracked by the DMT Code Clinical Trials Observatory, an open record of DMT-related clinical research.